For research use only. Not for therapeutic Use.
Zenarestat（Cat No.:M022934）is an aldose reductase inhibitor developed for the treatment of diabetic complications, particularly diabetic neuropathy. By inhibiting aldose reductase, an enzyme involved in the polyol pathway, Zenarestat prevents the accumulation of sorbitol in cells, which can lead to cellular damage and dysfunction. This action helps protect nerve cells from hyperglycemia-induced damage, potentially alleviating symptoms such as pain, numbness, and tingling in diabetic patients. Zenarestat’s targeted approach offers a promising therapeutic option for managing chronic complications associated with diabetes, improving patients’ quality of life.
| Catalog Number | M022934 |
| CAS Number | 112733-06-9 |
| Synonyms | 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid |
| Molecular Formula | C17H11BrClFN2O4 |
| Purity | ≥95% |
| IUPAC Name | 2-[3-[(4-bromo-2-fluorophenyl)methyl]-7-chloro-2,4-dioxoquinazolin-1-yl]acetic acid |
| InChI | InChI=1S/C17H11BrClFN2O4/c18-10-2-1-9(13(20)5-10)7-22-16(25)12-4-3-11(19)6-14(12)21(17(22)26)8-15(23)24/h1-6H,7-8H2,(H,23,24) |
| InChIKey | SXONDGSPUVNZLO-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C=C1Cl)N(C(=O)N(C2=O)CC3=C(C=C(C=C3)Br)F)CC(=O)O |
